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Abstract
Introduction: FTND (Fagerstrӧm test for nicotine dependence) and TTFC (time to smoke first cigar-
ette in the morning) are common measures of nicotine dependence (ND). However, genome-wide 
meta-analysis for these phenotypes has not been reported.
Methods: Genome-wide meta-analyses for FTND (N = 19,431) and TTFC (N = 18,567) phenotypes 
were conducted for adult smokers of European ancestry from 14 independent cohorts.
Results: We found that SORBS2 on 4q35 (p = 4.05 × 10−8), BG182718 on 11q22 (p = 1.02 × 10−8), 
and AA333164 on 14q21 (p = 4.11 × 10−9) were associated with TTFC phenotype. We attempted rep-
lication of leading candidates with independent samples (FTND, N = 7010 and TTFC, N = 10 061), 
however, due to limited power of the replication samples, the replication of these new loci did 
not reach significance. In gene-based analyses, COPB2 was found associated with FTND pheno-
type, and TFCP2L1, RELN, and INO80C were associated with TTFC phenotype. In pathway and net-
work analyses, we found that the interconnected interactions among the endocytosis, regulation 
of actin cytoskeleton, axon guidance, MAPK signaling, and chemokine signaling pathways were 
involved in ND.
Conclusions: Our analyses identified several promising candidates for both FTND and TTFC 
phenotypes, and further verification of these candidates was necessary. Candidates supported 
by both FTND and TTFC (CHRNA4, THSD7B, RBFOX1, and ZNF804A) were associated with addic-
tion to alcohol, cocaine, and heroin, and were associated with autism and schizophrenia. We also 
identified novel pathways involved in cigarette smoking. The pathway interactions highlighted the 
importance of receptor recycling and internalization in ND.
Implications: Understanding the genetic architecture of cigarette smoking and ND is critical to 
develop effective prevention and treatment. Our study identified novel candidates and biological 
pathways involved in FTND and TTFC phenotypes, and this will facilitate further investigation of 
these candidates and pathways.
Introduction
Cigarette smoking imposes a high health and financial toll on the 
smokers as well as society at large. Regular cigarette smoking often 
leads to nicotine dependence (ND). The tendency to develop ND is 
influenced by both genetic predisposition and environmental factors. 
In recent years, genetic studies of ND have made significant pro-
gress, exemplified by the identification of the CHRNA5-CHRNA3-
CHRNB4, CHRNB3-CHRNA6, CHRNA4, and CYP2A6 loci.1–6 
However, variants identified in these genes explain only a small pro-
portion of heritability. For example, cigarettes smoked per day 
(CPD), a common measure used in ND studies, explained about 
5.6% of the heritability.7 Many more risk genes remain unidentified.
Cigarette smoking is a complex behavior, and different meas-
ures are used to assess ND in both clinical and research settings. 
The quantity of consumption, typically assessed by self-reported 
CPD, is a measure used in many studies, including those that iden-
tified the CHRNA5-CHRNA3-CHRNB4, CHRNB3-CHRNA6, 
and CYP2A6 loci.2–4 The Fagerström Test for Nicotine Dependence 
(FTND)8 is another commonly used measure in genetic studies. CPD 
is one of the six questions included in the FTND and accounts up to 
three points in the 10-point FTND scale. Another FTND question, 
“How soon after you wake up do you smoke your first cigarette?” or 
time to smoke first cigarette in the morning (TTFC), is a strong pre-
dictor of difficulty to quit smoking and smoking relapse,9,10 COPD,11 
and lung cancer.12 Although both FTND and TTFC are important 
measures of ND, comparing with CPD, only a few genome-wide 
association studies (GWASs)6,13–15 have been conducted using these 
phenotypes. CHRNA4 and a few intergenic loci were found to be 
associated with FTND,6,13 but no locus for TTFC was identified.
Here we report results from our GWAS meta-analyses on FTND 
(N = 19 431) and TTFC (N = 18 567). Our motivation to analyze 
TTFC separately is to understand what genetic factors contributing 
to the difficulty of quitting and relapse. Another benefit is that we 
can compare the results between FTND and TTFC phenotypes and 
identify convergent candidates. A  lesson learned from comprehen-
sive studies of the CHRNA5-CHRNA3-CHRNB4 locus is that 
a true signal can be detected with many correlated phenotypes.16 
Hence, a candidate with corroborative support from both FTND 






/ntr/article/22/6/900/5531116 by Vrije U
niversiteit Am
sterdam
 user on 14 January 2021
902 Nicotine & Tobacco Research, 2020, Vol. 22, No. 6
Methods
Datasets
We assembled 14 independent cohorts (FTND, N = 19 431; TTFC, 
N  =  18  567) to examine the association between FTND/TTFC 
phenotypes and genome-wide genetic variants. A description of the 
cohorts and the summary of descriptive statistics of the cohorts are 
provided in Supplementary Material and Supplementary Table S1, 
respectively.
Genotype Quality Control and Imputation
Genotype quality controls were conducted separately by individual 
groups for the discovery data sets ISIB, ALSPAC, AUTW, CEDAR, 
FTC1, FTC2, NTR, and GCD. For discovery data sets obtained 
from dbGaP (http://www.ncbi.nlm.nih.gov/gap) (SAGE, SC, MGS, 
COPDGene1, CIDR370v1, CIDR370v3, CIDRc3, CIDRc4, and 
EAGLE), we used the genotypes provided by the original investigators 
who conducted quality control procedures following the dbGaP stand-
ards. Genotype imputations were also conducted separately by each 
group using MaCH17,18 or IMPUTE219,20 with the 1000 Genomes ref-
erence haplotypes (EUR panel, March 2012 release), using the default 
settings of the programs. Similarly, genotype quality control for the rep-
lication data sets (VTSABD, COPDGene2, S4S, PNAT2, and EAGLE 
[used for TTFC only]) was conducted by each group separately.
Inclusion Criteria and Phenotypes
Regular smokers, defined as those who smoked daily for at least 
1 month or those who smoked at least 100 cigarettes lifetime, of 
European ancestry were included. FTND scores (0–10) and TTFC 
scores (0–3) were obtained from self-reported FTND questionnaire, 
ascertaining the smoking behaviors during the heaviest smoking 
period of the smokers. Both FTND and TTFC scores were treated as 
quantitative traits without transformation.
Association and Meta-Analyses
GWAS analyses were performed separately for each data set by indi-
vidual groups using the PLINK program.21 Assuming a linear mixed 
effect model, FTND and TTFC were treated as continuous outcomes 
and genotypes as predictors, whereas sex, age, and the first 10 prin-
cipal components were included as covariates. Summary statistics 
from each data set were combined by GWAMA22 program using in-
verse variance-weighted meta-analysis approach with fixed effects. 
Because the individual samples were analyzed using the same model, 
the summary statistics were used directly without further normal-
ization. For the meta-analyses, only bi-allelic single nucleotide 
polymorphisms (SNPs) with minor allele frequency ≥1% and with 
high imputation quality (INFO value ≥ 0.4 from IMPUTE2, or r2 ≥ 
0.4 from MaCH) were included. p-Values from the meta-analyses 
were corrected for genomic-control. p-Values below 5 × 10−8 were 
considered as genome-wide significant, whereas p-values below 5 × 
10−5 were considered as suggestive association and this threshold 
was used for selection of loci for convergence analysis.
SNP Heritability Analyses
To estimate the SNP heritability with genome-wide data, we used 
the linkage disequilibrium (LD)–adjusted kinship algorithm.23,24 
Specifically, we used the control subjects from two large studies25,26 
as reference to select LD-adjusted SNP predictors and used the meta-
analysis results from the FTND and TTFC to estimate the weights 
for these SNPs. The heritability was then estimated with these 
LD-tagged SNPs. The number of SNPs used for FTND heritability 
estimate was 2 857 113 and that for TTFC was 2 981 471.
Replication Analyses
Six independent data sets of European descent (N = 7010 for FTND 
and N  =  10  061 for TTFC) were used for a replication study of 
selected SNPs. We conducted replication study for all loci meeting 
these four criteria: (1) having five or more SNPs with p-value ≤ 5 × 
10−5; (2) at least one SNP with p-value ≤ 5 × 10−5 having a minor al-
lele frequency ≥5%; (3) minor allele frequency variation at the locus 
> 5% between SNPs with p-value ≤ 5 × 10−5; and (4) at least four 
data sets contributed to the signal at the locus. For each locus, we 
selected the SNP with smallest p-value for replication testing. The 
selection of these criteria was based on lessons learned from recent 
GWASs where true loci have multiple associated SNPs with different 
frequencies and many loci have multiple independent signals.16,27 The 
requirement of 5% minor allele frequency was intended to minimize 
the influence of potential outlier SNPs, and the inclusion of variation 
of minor allele frequency was to maximize the likelihood that the 
locus could harbor more than one association signal. p-Values below 
.0031 (.05/16) were considered as significant replication.
Gene-Based Association Analyses
We performed gene-based association analyses using the results 
from the GWAS meta-analyses. Specifically, we used the Knowledge-
based mining system for Genome-wide Genetic studies (KGG) soft-
ware,28,29 which uses an extended Simes test to integrate functional 
information and association evidence to combine the SNP p-values 
within a gene to obtain an overall p-value for each gene. In these 
analyses, we filtered out SNPs found in less than four data sets. All 
analyses were conducted using KGG default settings. We used the 
Benjamini–Hochberg method30 to correct for multiple testing, and 
considered FDR q-values below 0.05 as statistically significant.
Pathway and Network Analyses
We conducted pathway enrichment analysis for genes with at least 
one marker with p ≤ 5 × 10−5 from GWAS meta-analyses of either 
FTND or TTFC. If a marker was within a gene region, it was as-
signed to the gene; otherwise, it was mapped to its most proximate 
gene using the 50-kb flanking regions (both 5′ and 3′ sides). Genes 
identified using SNPs associated with FTND and TTFC were merged 
for the pathway enrichment analyses. We used the hypergeometric 
test implemented in the tool WebGestalt (2014 update)31,32 and the 
canonical pathways from the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database. We required each pathway to have at 
least three genes from our gene list and no more than 300 genes 
from the reference genome. The p-values from hypergeometric tests 
were further adjusted by the Benjamini–Hochberg method.30 Only 
pathways with adjusted p-values < .05 were considered statistically 
significantly enriched.
We further examined how enriched pathways interacted with 
each other in function and regulation. Specifically, we applied the 
Characteristic Sub-Pathway Network (CSPN) algorithm33 to search 
for significantly interacting pathway pairs.34 CSPN was designed to 
prioritize pathway pairs with significant interaction of molecules 
from each pathway pair in the human protein–protein interaction 
(PPI) network (details in ref. 33). We used the human PPI data from 
the Protein Interaction Network Analysis (PINA) platform35 as the 
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PPI network included a total of 11 318 nodes (protein-coding genes) 
and 67 936 interactions. We restricted the analysis specifically to the 
aforementioned merged gene set and their enriched pathways. When 
running CSPN, a mode “OR” was selected, i.e., we considered all 
PPIs formed by the supplied genes as well as their one-step extension. 
In the final step, we selected the significant pathway interaction pairs 
based on permutation p-values ≤ .05.
Results
FTND and TTFC GWAS Meta-Analyses
In the GWAS meta-analyses of the discovery sample, about 19 000 
subjects from 14 independent cohorts were included. For FTND 
(N  =  19  431), only the CHRNA5-CHRNA3-CHRNB4 locus 
reached genome-wide significance (Table 1). The smallest p-value 
was observed at rs16969968 (β = −0.21, SE = 0.02, p = 3.96 × 10−19), 
which is a functional variant in CHRNA5 known to influence 
smoking behavior, in particular the quantity of cigarettes smoked. 
Several additional loci (CIB4 on 2p23, BG182718 on 11q22, and 
DSC3 on 18q12) were promising (Table 1). The meta-analysis had 
a lambda of 1.03, indicating no significant genomic inflation. The 
Manhattan and Q-Q plots for FTND are shown in Supplementary 
Figure S1. In the analyses of TTFC (N = 18 567), four loci (SORBS2 
on 4q35, BG182718 on 11q22, AA333164 on 14q21, and 
CHRNA5-CHRNA3-CHRNB4 on 15q25) reached genome-wide 
significance (Table 1). A closer examination of the local linkage dis-
equilibrium (LD) indicated that the signals from BG182718 and 
CHRNA5-CHRNA3-CHRNB4 covered a broad genomic region 
(~500 kb), whereas the signals from SORBS2 and AA333164 were 
restricted within small intervals (Figure S2). CHRNB3-CHRNA6 
(smallest p = 8.83 × 10−8 for rs11785369) and MIR31HG (smallest 
p = 5.70 × 10−8 for rs184042824) were approaching genome-wide 
significance. Several loci meeting our criteria for replication testing 
are also listed in Table 1. No genomic inflation was observed for 
TTFC phenotype (λ  =  1.01). The Manhattan and Q–Q plots for 
TTFC are shown in Supplementary Figure S1.
Table 1. The most significant loci identified in the FTND and TTFC GWAS meta-analyses in the discovery sample
CHR BP SNP EA NEA EAF β SE Z p N Effect* GENE
FTND 2 26,860,822 rs17005545 T C 0.94 −0.23 0.05 −4.97 6.99E-07 18621 ------+-------- CIB4
11 97,713,579 rs117029742 T C 0.98 −0.64 0.12 −5.32 1.04E-07 12977 --------??-?-+? BG182718
15 78,882,925 rs16969968 G A 0.64 −0.21 0.02 −8.83 3.96E-19 17860 -----------?-+- CHRNA5
18 28,355,510 rs28510557 C T 0.60 −0.10 0.02 −4.85 1.23E-06 18673 ----++-+----+-- DSC3
TTFC 1 40,464,894 rs34022242 C G 0.94 −0.13 0.02 −5.16 2.48E-07 14286 ----------+?--?? MFSD2A
1 68,862,622 rs3125927 G A 0.64 −0.05 0.01 −5.02 5.24E-07 16091 ----------+----? RPE65
4 103,715,385 rs223441 C T 0.51 0.05 0.01 4.58 4.66E-06 18533 ++++-+++++++-+++ CISD2
4 186,514,078 rs28567706 C G 0.99 0.49 0.09 5.49 4.05E-08 6533 +?????+????++??? SORBS2
8 42,527,386 rs11785369 A C 0.89 0.09 0.02 5.35 8.83E-08 18634 ++++++++++-++-++ CHRNB3
9 21,673,859 rs184042824 C T 0.98 −0.31 0.06 −5.43 5.70E-08 9005 -+--?+?--?????-? MIR31HG
11 97,713,579 rs117029742 T C 0.98 −0.30 0.05 −5.73 1.02E-08 13061 ---------?+-?++? BG182718
14 44,608,436 rs10133756 C G 0.98 −0.31 0.05 −5.88 4.11E-09 13283 ---??----?-??++- AA333164
15 78,882,925 rs16969968 G A 0.66 −0.06 0.01 −5.82 6.21E-09 17834 ----------+-?+-- CHRNA5
17 51,940,280 rs2877510 C T 0.17 0.06 0.01 4.52 6.36E-06 18647 ++++--++-+-++-++ KIF2B
20 15,901,883 rs6135601 G T 0.97 −0.13 0.03 −4.55 5.53E-06 18644 -----+----+----- MACROD2
22 42,058,846 rs132786 G A 0.19 −0.07 0.01 −4.61 4.07E-06 14605 --?--------?---- XRCC6
EA, effect allele; NEA, non-effect allele; EAF, effect allele frequency; BP, base-pair position according to GRCh37/hg19; FTND, Fagerström Test for Nicotine 
Dependence; TTFC, time to first cigarette. *, minus and plus signs refer to the direction of effect in each independent dataset (SAGE, SC, MGS, COPDGene1, 
ISIB, CIDR370v1, CIDR370v3, CIDRc3, CIDRc4, EAGLE, ALSPAC, AUTW, VTSABD, CEDAR, FTC1, FTC2, NTR, GCD), whereas “?” refers to missing data. 
Genome-wide significant signals are highlighted in bold.
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For FTND, four loci were selected for replication in sev-
eral independent samples (Table 2). Of the four loci tested, only 
rs16969968 at the CHRNA5-CHRNA3-CHRNB4 locus was suc-
cessfully replicated (p = 1.19 × 10−11). Rs17005545 in the novel 
locus CIB4 had a p-value of 2.68  × 10−7 in the combined sam-
ples. For TTFC, rs16969968 in CHRNA5 and 11 other loci were 
selected for replication. Rrs16969968 in CHRNA5 (p  =  2.84  × 
10−10) was successfully replicated and rs11785369 near the 
CHRNB3 gene reached genome-wide significance in the combined 
samples (Table 2).
We conducted SNP heritability analyses for both FTND and 
TTFC using the LD-adjusted kinship algorithm.23,24 The SNP her-
itability for FTND was estimated at 0.645, and that for TTFC was 
0.193.
Convergent Loci Between FTND and TTFC
We compared the results obtained for FTND and TTFC to 
identify genes showing convergent association signals. We then 
selected genes/loci showing suggestive association (p ≤ 5 × 10−5) 
Table 2. Replication of candidates for FTND and TTFC
Marker Info Discovery Replication Combined
 CHR BP SNP EA NEA GENE β SE p β SE p β SE p
FTND 2 26,860,822 rs17005545 T C CIB4 −0.23 0.05 6.99E-07 −0.16 0.10 0.1078 −0.22 0.04 2.68E-07
11 97,713,579 rs117029742 T C BG182718 −0.64 0.12 1.04E-07 0.29 0.19 0.1370 −0.38 0.10 1.73E-04
15 78,882,925 rs16969968 G A CHRNA5 −0.21 0.02 3.96E-19 −0.29 0.04 1.19E-11 −0.23 0.02 4.24E-28
18 28,355,510 rs28510557 C T DSC3 −0.10 0.02 1.23E-06 0.02 0.04 0.6672 −0.08 0.02 3.19E-05
TFC 1 40,464,894 rs34022242 C G MFSD2A −0.13 0.02 2.48E-07 −0.05 0.04 0.1643 −0.11 0.02 3.53E-07
1 68,862,622 rs3125927 G A RPE65 −0.05 0.01 5.24E-07 0.02 0.02 0.2298 −0.03 0.01 2.25E-04
4 103,715,385 rs223441 C T CISD2 0.05 0.01 4.66E-06 −0.01 0.02 0.4071 0.03 0.01 4.42E-04
4 186,514,078 rs28567706 C G SORBS2 0.49 0.09 4.05E-08 0.08 0.07 0.2745 0.23 0.05 2.22E-05
8 42,527,386 rs11785369 A C CHRNB3 0.09 0.02 8.83E-08 0.06 0.03 2.46E-02 0.08 0.01 7.88E-09
9 21,673,859 rs184042824 C T MIR31HG −0.31 0.06 5.70E-08 −0.03 0.09 0.7136 −0.23 0.05 1.53E-06
11 97,713,579 rs117029742 T C BG182718 −0.30 0.05 1.02E-08 0.07 0.07 0.3574 −0.17 0.04 5.28E-05
14 44,608,436 rs10133756 C G AA333164 −0.31 0.05 4.11E-09 0.04 0.07 0.5277 −0.18 0.04 1.26E-05
15 78,882,925 rs16969968 G A CHRNA5 −0.06 0.01 6.21E-09 −0.10 0.02 2.84E-10 −0.07 0.01 1.05E-17
17 51,940,280 rs2877510 C T KIF2B 0.06 0.01 6.36E-06 0.01 0.02 0.5735 0.04 0.01 4.45E-05
20 15,901,883 rs6135601 G T MACROD2 −0.13 0.03 5.53E-06 0.02 0.04 0.5457 −0.08 0.02 8.18E-04
22 42,058,846 rs132786 G A XRCC6 −0.07 0.01 4.07E-06 0.02 0.02 0.2141 −0.03 0.01 5.29E-03
EA, effect allele; NEA, noneffect allele; EAF, effect allele frequency; BP, base-pair position according to GRCh37/hg19; FTND, Fagerström Test for Nicotine 
Dependence; TTFC, time to first cigarette. Loci reaching GWAS significance (5E-8) were highlighted in bold.
Table 3. Genes/loci showing convergent association between FTND and TTFC
Marker Info FTND TTFC
CHR BP SNP EA NEA EAF β SE p β SE p GENE
2 4,073,151 rs13425218 G C 0.68 −0.13 0.03 3.80E-05 −0.06 0.01 2.11E-05 DA409732
2 137,983,050 rs17269864 C A 0.67 −0.10 0.02 2.77E-06 −0.04 0.01 3.17E-05 THSD7B*
2 185,787,483 rs56321552 G C 0.95 0.24 0.06 2.20E-05 NL NL NL ZNF804A**
2 185,639,136 rs78011041 T G 0.97 NL NL NL 0.12 0.03 3.42E-05 ZNF804A**
2 221,852,642 rs6709809 G A 0.96 −0.24 0.06 4.18E-05 −0.13 0.03 2.59E-06 —
5 30,863,015 rs4502841 G A 0.48 −0.09 0.02 1.46E-05 −0.05 0.01 2.14E-06 —
5 92,486,203 rs4526087 C G 0.90 0.15 0.03 1.15E-05  NL NL NL —
5 92,554,821 rs193049029 T C 0.98 NL NL NL −0.24 0.06 2.78E-05 —
8 42,527,386 rs11785369 A C 0.90 0.14 0.03 2.28E-05 0.09 0.02 8.83E-08 CHRNB3-CHRNA6
9 136,789,062 rs7847503 A G 0.97 −0.23 0.06 4.32E-05 NL NL NL VAV2
9 136,768,563 rs10993850 C A 0.91 NL NL NL 0.08 0.02 3.93E-05 VAV2
11 72,301,503 rs341047 G A 0.88 −0.14 0.03 3.07E-05 −0.06 0.02 3.83E-05 PDE2A
11 97,713,579 rs117029742 T C 0.98 −0.64 0.12 1.04E-07 −0.30 0.05 1.02E-08 BG182718
15 78,882,925 rs16969968 G A 0.64 −0.21 0.02 3.96E-19 −0.06 0.01 6.21E-09 CHRNA5-CHRNA3-CHRNB4
16 6,124,714 rs9927211 G C 0.23 −0.13 0.03 1.83E-05 NL NL NL RBFOX1 ***
16 6,071,910 rs12444143 T C 0.40 NL NL NL −0.05 0.01 3.56E-05 RBFOX1 ***
17 51,926,097 rs3966061 C T 0.17 0.12 0.03 2.14E-05 0.06 0.01 1.46E-05 KIF2B
20 61,989,658 rs45623037 G C 0.92 −0.21 0.05 2.75E-05 NL NL NL CHRNA4
20 60,522,424 rs4925328 T G 0.43 NL NL NL 0.05 0.01 4.78E-05 CHRNA4
22 36,503,250 rs16996373 G T 0.84 −0.12 0.03 3.18E-05 −0.06 0.01 8.93E-06 APOL3
EA, effect allele; NEA, noneffect allele; EAF, effect allele frequency; BP, base-pair position according to GRCh37/hg19; FTND, Fagerström Test for Nicotine 
Dependence; TTFC, time to first cigarette; NL, not listed because the p-value > 5 × 10−5; *, linked to alcohol addiction; 43 **, linked to schizophrenia; 58,59 ***, linked 
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in both FTND and TTFC meta-analyses. A total of 15 genes/loci 
with convergent association signals were found (Table 3). The 
CHRNA5-CHRNA3-CHRNB4 locus was the only one reaching 
genome-wide significance for both FTND and TTFC. Other nico-
tinic receptors, CHRNB3-CHRNA6 and CHRNA4, also showed 
convergent association signals. Other highlighted genes included 
long noncoding RNAs (DA409732 and BG182718) and a RNA-
binding gene (RBFOX1), microtubule and actin regulation genes 
(KIF2B and VAV2), a cAMP/cGMP modulating gene (PDE2A), 
and an apolipoprotein gene (APOL3). For some genes (THSD7B, 
PDE2A, KIF2B, and APOL3), the same SNPs showed suggestive 
association for both phenotypes; for other genes (ZNF804A, 
VAV2, RBFOX1, and CHRNA4), the association signals for the 
two phenotypes were from different SNPs.
Gene-Based Meta-Analyses
We conducted gene-based analyses using the KGG program. In these 
analyses, in addition to the CHRNA5 locus and nearby genes, a 
few novel genes were identified (Table 4). COPB2 and CHRNA4 
reached significance for association with FTND, and TTFCP2L1, 
RELN, and INO80C were significant for the TTFC phenotype. 
Table 4 also lists other candidates from gene-based analyses (i.e., 
genes with q-value ≤ 0.1).
Pathway and Network Analyses
There were 647 SNPs with p-value ≤ 5 × 10−5 in the FTND meta-
analysis and they were mapped to 134 known genes. There were 
936 markers with p-value ≤ 5  × 10−5 in the TTFC meta-analysis 
and they were mapped to 145 genes. Altogether 15 genes were 
shared between the two phenotypes, yielding a total of 265 unique 
genes for pathway analyses. In the enrichment analyses using ca-
nonical pathways defined in KEGG database, a total of 26 path-
ways were found to be overrepresented among these genes (Table 5). 
The neuroactive ligand–receptor interaction pathway was the most sig-
nificantly enriched pathway, including nicotinic receptors (CHRNA5, 
CHRNA3, CHRNB4, CHRNB3, CHRNA6, and CHRNA4), 
gamma-aminobutyric acid receptor (GABRG3), glutamate receptor 
(GRM5), and somatostatin receptors (SSTR1 and SSTR4). In addition 
to several pathways known to be involved in ND (cell adhesion mol-
ecules, MAPK signaling, tight junction, and axon guidance), our ana-
lyses suggested that endocytosis, lysosome, chemokine signaling, and 
regulation of actin cytoskeleton pathways are also involved in ND.
We further tested if and how these pathways interacted with 
each other. Multiple immune related pathways were identified by 
two highlighted genes, HLA-DMB and HLA-DRB5; to avoid the 
extensive network of HLA-related immune responses, we excluded 
these two genes in our pathway crosstalk analyses. Our analyses re-
vealed interacting networks among the endocytosis, regulation of 
Table 4. Summary of gene-association results
Gene Information FTND TTFC
Functions*Name Chr Position P_value FDR q_value P_value FDR q_value
RPE65 1 68894506 0.49513 1.0000 0.00004 0.0673 congenital amaurosis
CHD1L 1 146714290 0.04676 0.7808 0.00003 0.0636 cancer gene
TTFCP2L1 2 121974163 0.89730 1.0000 0.00001 0.0279 pluripotency, development
COPB2 3 139076432 0.00001 0.0229 0.64899 1.0000 lung cancer
LOC102723704 4 103698193 0.08404 0.8275 0.00004 0.0673 ncRNA
UBE2D3 4 103715539 0.12397 0.8807 0.00005 0.0674 ubiquitination
LOC105377348 4 103750470 0.32928 1.0000 0.00006 0.0676 ncRNA
CISD2 4 103790134 0.36281 1.0000 0.00004 0.0673 intracellular calcium homeostasis
SLC9B1 4 103822084 0.51668 1.0000 0.00004 0.0673 sodium/hydrogen exchanger
DNAH8 6 38683116 0.16941 0.9251 0.00006 0.0676 sperm and respiratory cilia motility
AGR3 7 16899029 0.37663 1.0000 0.00008 0.0827 cancer gene
RELN 7 103112230 0.31646 1.0000 4.47E-06 0.0223 schizophrenia, autism, cell adhesion
CHRNB3 8 42552561 0.03471 0.7313 0.00005 0.0674 nicotinic receptor
MIR31HG 9 21454266 0.03006 0.7241 0.00005 0.0676 lncRNA, cancer regulation
LOC389765 9 88420916 0.06893 0.8117 0.00006 0.0698 —
TMEM132B 12 126106997 0.19739 0.9368 0.00009 0.0847 intracranial aneurysm
SLC46A3 13 29274217 0.54791 1.0000 0.00004 0.0673 Lysosome/cytoplasm transport
KLHL1 13 70274724 0.00271 0.4838 0.00002 0.0579 calcium signaling, cancer
IREB2 15 78730517 9.55E-11 4.76E-07 0.00014 0.1254 lung diseases
HYKK 15 78799905 3.59E-17 8.93E-13 1.20E-07 9.92E-04 lung diseases
PSMA4 15 78832746 7.80E-11 4.76E-07 1.76E-05 5.48E-02 lung diseases
CHRNA5 15 78857861 1.53E-15 1.27E-11 9.51E-08 9.92E-04 nicotinic receptor
CHRNA3 15 78887646 1.00E-15 1.25E-11 6.26E-08 9.92E-04 nicotinic receptor
CHRNB4 15 78916635 1.47E-10 6.12E-07 2.60E-06 1.62E-02 nicotinic receptor
INO80C 18 33048290 0.07345 0.8117 1.01E-05 0.0359 chromatin remodeling/silencing
SSTR4 20 23016056 0.23580 0.9667 2.32E-05 0.0579 somatostatin receptors
CHRNA4 20 61974661 1.39E-06 0.0049 0.0013 0.3773 nicotinic receptor
XRCC6 22 42017345 0.09636 0.8438 0.0001 0.0724 cancer gene
NHP2L1 22 42069936 0.30160 0.9951 0.0001 0.0835 chromatin remodeling/silencing
MEI1 22 42095517 0.42723 1.0000 0.0001 0.0676 meiotic chromosome synapsis
FTND, Fagerström Test for Nicotine Dependence; TTFC, time to first cigarette; *, functions relevant to smoking or neuropsychiatric co-morbidities are highlighted 
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actin cytoskeleton, MAPK signaling, axon guidance, and chemokine 
signaling pathways (Figure 1). We also saw that two other pathways, 
melanogenesis and basal cell carcinoma, interacted and contributed 
to ND phenotypes.
Conclusion and Discussion
We conducted GWAS meta-analyses for the FTND and TTFC 
phenotypes in about 19 000 regular smokers of European ancestry 
from 14 independent cohorts. We confirmed the known association 
of the functional variant D398N (rs16969968) in the CHRNA5-
CHRNA3-CHRNB4 locus for both FTND and TTFC phenotypes. 
Although the association between FTND and CHRNA5-CHRNA3-
CHRNB4 locus had been reported before, ours is the first to report 
its association with TTFC. GWAS meta-analysis of FTND identified 
one potential novel locus (CIB4 on 2p23) with suggestive association 
in the discovery samples and a trend in the replication samples. CIB4 
encodes a calcium binding protein that interacts with integrin.36 It 
may be involved in the integrin signaling. Our GWAS meta-analyses 
of TTFC, the largest for this phenotype, identified three novel loci 
(SORBS2 on 4q35, BG182718 on 11q22, and AA333164 on 14q21) 
in the discovery samples. SORBS2 encodes an adaptor protein in-
volved in the regulation of actin cytoskeleton37 and is recently sug-
gested to be involved in intellectual disability.38 The 11q22 signal 
peaks at rs117029742 located 25 kb from the 3′ end of BG182718 
(also referred to as RP11-379J13.2). BG182718 is a long noncoding 
RNA with unknown function. In the interval of 1.5 MB centered 
at rs117029742, there are no other known genes. Interestingly, 
ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/) reports 
multiple large copy number variants in this region and these vari-
ants are reported to be associated with developmental disabilities.39 
AA333164 (also referred to as RP11-305B6.3) on 14q21 is another 
long noncoding RNA with unknown function; it also overlaps with 
known copy number variants associated with global developmental 
Table 5. Summary of pathway enrichment analyses
Pathway Genes Found in the Pathway

















272 11 1.65 6.66 1.03E-06 5.56E-05
Endocytosis AP2A2,EHD3,FGFR2,IQSEC1,MET,RAB5C 201 6 1.22 4.91 0.0015 0.0405
Intestinal immune 
network for IgA 
production
HLA-DMB,HLA-DRB5,IL15 48 3 0.29 10.29 0.0031 0.0540
Lysosome AP1S3,LIPA,MANBA,SUMF1 121 4 0.74 5.44 0.0065 0.0694
Protein export SPCS3,SRP9 23 2 0.14 14.31 0.0086 0.0694
Cell adhesion molecules 
(CAMs)





CACNA1D,CACNG4,CTNNA3 74 3 0.45 6.67 0.0105 0.0709
Dilated cardiomyopathy ADCY4,CACNA1D,CACNG4 90 3 0.55 5.49 0.0177 0.0816
Purine metabolism ADCY4,PAPSS2,PDE2A,PDE4B 162 4 0.98 4.06 0.0174 0.0816
Huntington’s disease AP2A2,GRM5,PPARG,TAF4 183 4 1.11 3.60 0.0259 0.0816
MAPK signaling pathway CACNA1D,CACNG4,DUSP16,FGFR2,MRAS 268 5 1.63 3.07 0.0244 0.0816
Melanogenesis ADCY4,FZD8,WNT16 101 3 0.61 4.89 0.0239 0.0816
Allograft rejection HLA-DMB,HLA-DRB5 37 2 0.22 8.90 0.0213 0.0816
Type I diabetes mellitus HLA-DMB,HLA-DRB5 43 2 0.26 7.66 0.0282 0.0816
Asthma HLA-DMB,HLA-DRB5 30 2 0.18 10.97 0.0143 0.0816
Graft-versus-host disease HLA-DMB,HLA-DRB5 41 2 0.25 8.03 0.0258 0.0816
Rheumatoid arthritis HLA-DMB,HLA-DRB5,IL15 91 3 0.55 5.43 0.0182 0.0816
Chemokine signaling 
pathway
ADCY4,TIAM2,VAV2,XCL1 189 4 1.15 3.48 0.0287 0.0816
Regulation of actin 
cytoskeleton
FGFR2,MRAS,TIAM2,VAV2 213 4 1.29 3.09 0.0416 0.0944
Autoimmune thyroid 
disease
HLA-DMB,HLA-DRB5 52 2 0.32 6.33 0.0400 0.0944
Hedgehog signaling 
pathway
RAB23,WNT16 56 2 0.34 5.88 0.0457 0.0944
Basal cell carcinoma FZD8,WNT16 55 2 0.33 5.99 0.0442 0.0944
Tight junction CTNNA3,EPB41L1,MRAS 132 3 0.8 3.74 0.0469 0.0944
Inositol phosphate 
metabolism
IMPA1,MINPP1 57 2 0.35 5.78 0.0472 0.0944
Axon guidance MET,NTNG1,ROBO2 129 3 0.78 3.83 0.0443 0.0944
Staphylococcus aureus 
infection
HLA-DMB,HLA-DRB5 55 2 0.33 5.99 0.0442 0.0944
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delay.39 It is not clear how TTFC relates to intellectual disability 
or developmental delay, or whether there are other functions that 
account for the association. Independent replication of the three 
novel loci for TTFC was not evident, presumably due to the lack of 
power of the replication samples. Statistically significant evidence 
for independent replication of the observed SNP associations may 
require even larger sample sizes.
FTND is a commonly used measure in studies of smoking be-
havior and ND. It consists of six questions, with a sum score ranging 
from 0 to 10.8 Many studies have used FTND scores to define ND, 
with varying thresholds (e.g., FTND ≤ 3 as low ND and > 6 as high 
ND, but also FTND ≥4 as dependent and FTND = 0 as unaffected 
and those in-between as uncertain), whereas others have treated 
FTND as a quantitative trait. Hancock and colleagues6 conducted 
a GWAS using categorized FTND (low-level smoking and mild ND 
[FTND = 0 to 3]; moderate ND [FTND = 4 to 6]; and severe ND 
[FTND = 7 to 10]) and discovered that CHRNA4 was associated 
with FTND at genome-wide significance across GWAS discovery 
and replication samples. Loukola and colleagues14 used FTND as 
a binary trait (FTND ≥ 4 as affected) in a study of 1,114 Finns but 
detected no genome-wide significant associations. Gelernter and col-
leagues13 conducted a GWAS with FTND as a quantitative trait in 
a sample of 4117 Caucasians and 3529 African Americans, and de-
tected a genome-wide significant signal in an intergenic region on 
7q21. In our analyses, which included the Caucasian subjects from 
the study of Gelernter and colleagues, only the CHRNA5-CHRNA3-
CHRNB4 locus reached genome-wide significance. When the dis-
covery and replication samples were combined, the signal amplified. 
The signal observed in Gelernter et al.’s study,13 rs13225753, was not 
significant in our analyses (p = .7188), presumably due to heterogen-
eity at the locus (Cochran’s Q = 36.86, p = 4.36 × 10−4).
Compared with FTND, the TTFC phenotype is more related to 
the ability to quitting and relapse.9 Loukola and colleagues14 con-
ducted a GWAS of TTFC in 1114 Finnish subjects, but detected 
no genome-wide significant signals. In our discovery sample, which 
also included the subjects from the study of Loukola and col-
leagues,14 we found four loci reaching genome-wide significance 
(Table 1). When the discovery and replication samples were com-
bined, the CHRNA5-CHRNA3-CHRNB4 locus remained genome-
wide significant for both phenotypes and the CHRNB3-CHRNA6 
locus reached genome-wide significance for TTFC, whereas the sig-
nals of other loci decreased somewhat due to weaker magnitudes 
of association in the replication samples (the common “winner’s 
curse” phenomenon40). The CHRNB3-CHRNA6 locus was origin-
ally identified using CPD phenotype,3 and in the current study, a 
much stronger signal was detected for TTFC (min p = 8.83 × 10−8 
for rs11785396) compared with FTND (minimal p = 2.28 × 10−5 for 
rs11785396; see Table 3). This is consistent with a previous report 
that the signal at the CHRNB3-CHRNA6 locus is stronger when 
analyzed with FTND phenotype than that of CPD,15 because the 
main difference between FTND score and CPD is largely contrib-
uted by TTFC score.
TTFC is a component of FTND, and therefore TTFC scores 
correlate with FTND scores. In the literature, the correlation coef-
ficient was reported to be 0.57.41 In the SC sample, the correlation 
coefficient was 0.69. However, when we examined the meta-
analysis results from these phenotypes, we saw notable differences. 
For markers reaching genome-wide significance, the CHRNA5-
CHRNA3-CHRNB4 locus was the only region showing overlap. 
Even for this locus, the strength of signal differed substantially 
between FTND (minimal p  =  3.96  × 10−19 for rs16969968) and 
TTFC (minimal p = 6.21 × 10−9 for rs16969968), despite similar ef-
fective sample sizes (Table 1). BG182718 (tagged by rs117029742) 
also showed signals for both phenotypes, with stronger association 
with TTFC (p  = 1.02 × 10−8) compared with FTND (p  = 1.04 × 
10−7). On the other hand, there were genes/loci that showed as-
sociation with one phenotype but not the other. For example, 
CIB4 (tagged by rs17005545) showed suggestive association with 
FTND (p  =  6.99  × 10−7), but very weak evidence of association 
with TTFC (p  =  2.15  × 10−4). Similarly, rs34022242 located be-
tween MFSD2A and CAP1 showed suggestive association with 
TTFC (p = 2.48 × 10−7), but no association with FTND (p = .024). 
This suggests that FTND and TTFC measure different aspects of 
ND. Based on this information, we reasoned that if some genes/
loci showed reasonable signals for both phenotypes, it could be 
seen as a convergent evidence that these genes/loci are likely genu-
inely associated with ND. Our convergent analyses identified sev-
eral intriguing genes in addition to those previously highlighted for 
ND (CHRNA5-CHRNA3-CHRNB4, CHRNB3-CHRNA6, and 
CHRNA46). These included genes previously associated with dis-
eases for which cigarette smoking is a significant risk factor, such as 
cocaine addiction (RBFOX1),42 alcohol dependence (THSD7B),43 
schizophrenia (ZNF804A)44 and heroin addiction45,46 (ZNF804A), 
rheumatoid arthritis (PDE2A),47 and prostate cancer (APOL3)48 
(Table 3). Furthermore, RBFOX1 was highlighted in a recent study 
on the genetic relationship between schizophrenia and ND.49 It re-
mains to be elucidated whether these genes are independent risk 
factors for these diseases among nonsmokers, or is the genetic as-
sociation arising from mediation or moderation by smoking. For 
example, the CHRNA5 D398N function variant (rs16969968) is 
a risk factor for lung cancer but only among smokers.50,51 Our re-
sults further reassured that for a true signal, such as the CHRNA5-
CHRNA3-CHRNB4 locus, convergent signals are seen with 
multiple-related phenotypes.
We also noticed the difference in SNP heritability estimates be-
tween the FTND and TTFC phenotypes. The SNP heritability esti-
mate of 0.645 for FTND was close to the heritability estimated from 
twin studies for ND.52 The estimate of 0.193 for TTFC seemed low 
when compared with twin studies,53 but it was close to the estimate 
of 0.154 from a study with SNP measure.54 The implication of this 
difference was not immediately clear. As SNP heritability estimates 
were influenced by the power of the GWASs, it was likely that our 
TTFC meta-analysis did not have the power to have a good estimate 
of heritability.
Gene-based analyses highlighted several other genes besides 
the CHRNA5-CHRNA3-CHRNB4 and CHRNA4 loci, including 
a gene involved in pluripotency demethylation and development 
(TTFCP2L1),55,56 a gene associated with lung cancer (COPB2),57 a 
gene implicated in schizophrenia (RELN),58,59 and a gene involved 
in chromatin remodeling (INO80C)60 (Table 4). These were novel 
genes first reported to be associated with smoking-related pheno-
types. It would be interesting to see whether these genes could be 
replicated in future studies. Our pathway analyses revealed two 
statistically significantly enriched pathways. Although the involve-
ment of neuroactive ligand-receptor interaction pathway in ND 
was expected since nicotinic receptors and other surface receptors 
belong to this pathway, the identification of endocytosis pathway 
in ND was novel and interesting. Over the years, there has been 
accumulating evidence that the recycling and internalization of 
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glutamate receptors,63 and opioid receptors,64 are involved in drug 
addiction. Furthermore, it is known that the recycling and intern-
alization of surface proteins are mediated and regulated by endo-
cytosis, actin cytoskeleton, and lysosome functions. Our pathway 
analyses explicitly identified these pathways in ND (Table 5). Our 
network analyses indicated that these pathways were interacting 
with each other, forming an interconnected network. These find-
ings were consistent with the emerging picture in addiction studies.
In summary, our GWAS meta-analyses of FTND and TTFC iden-
tified several promising candidates for both phenotypes. Three novel 
loci (SORBS2, BG182718, and AA333164) were discovered for 
TTFC. Although we could not validate these novel loci with stat-
istical significance in our replication sample, further investigation 
is warranted. With supporting information from both FTND and 
TTFC phonotypes, we also identified promising candidates for ND, 
including several genes known for association with other psychi-
atric disorders. Our pathway analyses highlighted the endocytosis 
pathway, supporting the importance of recycling and internalization 
of surface receptors in the development of nicotine addiction. In our 
network analyses, we discovered a multinode network with several 
interacting pathways known for involvement in substance abuse and 
psychiatric disorders. This information provides new insights for our 
understanding of ND and nicotine withdrawal.
Supplementary Material
Supplementary data are available at Nicotine and Tobacco Research online.
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